We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 24, 2022

PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit From Extended Adjuvant Capecitabine in Patients With TNBC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine
Clin. Cancer Res 2022 Nov 08;[EPub Ahead of Print], K Asleh, A Lluch, A Goytain, C Barrios, XQ Wang, L Torrecillas, D Gao, M Ruiz-Borrego, S Leung, J Bines, Á Guerrero-Zotano, JÁ García-Sáenz, JM Cejalvo, J Herranz, R Torres, J de la Haba-Rodriguez, F Ayala, H Gómez, F Rojo, TO Nielsen, M Martin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading